• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺部给药在现代治疗中的作用:概述

The Role of Pulmonary Drug Delivery in Modern Therapeutics: An Overview.

作者信息

Kumar Subramani Prem, P N Remya, Narayanasamy Damodharan

机构信息

Pharmacy, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, IND.

Pharmacy, SRM Institute of Science and Technology, Chennai, IND.

出版信息

Cureus. 2024 Sep 4;16(9):e68639. doi: 10.7759/cureus.68639. eCollection 2024 Sep.

DOI:10.7759/cureus.68639
PMID:39371739
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11451426/
Abstract

The pulmonary drug delivery system is a promising and evolving technology in which the prescribed medicine is breathed through the lungs, and subsequently, it enters the circulation via the alveolar epithelium. This category of pulmonary drug delivery system is an appealing and non-invasive administration method. Pulmonary drug delivery is most commonly utilized to treat airway problems by providing locally active medicines directly to their site of action. The dose required to have a pharmacological effect is reduced when medicines are delivered directly to their site of action. In addition to locally acting medications, the pulmonary route can be utilized to deliver compounds with systemic effects, such as in the case of insulin inhalation therapy for systemic absorption. Particle size, bioavailability, device compatibility, and other aspects must be addressed, including the formulation of drugs into an acceptable dosage for inhalation with sufficient stability. This formulation must also be used in conjunction with a suitable inhaler device that produces an aerosol with a particle or droplet size that assures deposition in the required targeted area of the pulmonary system. Recent advancements in pulmonary drug delivery include the development of targeted nanoparticles and inhalable biologics, which enhance drug absorption and efficacy while minimizing systemic side effects. Future directions focus on personalized medicine approaches and advanced inhalation technologies, although limitations such as variable patient adherence and the need for precise dosing continue to pose challenges.

摘要

肺部药物递送系统是一项很有前景且不断发展的技术,在该系统中,处方药物通过肺部吸入,随后经肺泡上皮进入血液循环。这类肺部药物递送系统是一种有吸引力的非侵入性给药方法。肺部药物递送最常用于通过直接将局部活性药物输送到其作用部位来治疗气道问题。当药物直接输送到其作用部位时,产生药理作用所需的剂量会降低。除了局部作用的药物外,肺部给药途径还可用于递送具有全身作用的化合物,例如胰岛素吸入疗法用于全身吸收的情况。必须解决粒径、生物利用度、装置兼容性等方面的问题,包括将药物制成具有足够稳定性的可接受吸入剂型。这种制剂还必须与合适的吸入装置配合使用,该装置产生的气雾剂的颗粒或液滴大小要确保在肺部系统所需的目标区域沉积。肺部药物递送的最新进展包括靶向纳米颗粒和可吸入生物制品的开发,它们可提高药物吸收和疗效,同时将全身副作用降至最低。未来的发展方向集中在个性化医疗方法和先进的吸入技术上,尽管诸如患者依从性不一和需要精确给药等限制仍然构成挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/861a/11451426/ef3f60bfd2e9/cureus-0016-00000068639-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/861a/11451426/8b9d6a641c77/cureus-0016-00000068639-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/861a/11451426/ef3f60bfd2e9/cureus-0016-00000068639-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/861a/11451426/8b9d6a641c77/cureus-0016-00000068639-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/861a/11451426/ef3f60bfd2e9/cureus-0016-00000068639-i02.jpg

相似文献

1
The Role of Pulmonary Drug Delivery in Modern Therapeutics: An Overview.肺部给药在现代治疗中的作用:概述
Cureus. 2024 Sep 4;16(9):e68639. doi: 10.7759/cureus.68639. eCollection 2024 Sep.
2
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
3
Advances in Pulmonary Drug Delivery.肺部给药的进展
Pharmaceutics. 2020 Sep 23;12(10):911. doi: 10.3390/pharmaceutics12100911.
4
[Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].《稳定期慢性气道疾病吸入装置规范应用中国专家共识(2023年版)》
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Nov 12;46(11):1055-1067. doi: 10.3760/cma.j.cn112147-20230411-00167.
5
Insulin inhalation--Pfizer/Nektar Therapeutics: HMR 4006, inhaled PEG-insulin--Nektar, PEGylated insulin--Nektar.胰岛素吸入剂——辉瑞/耐科斯特治疗公司:HMR 4006,吸入型聚乙二醇化胰岛素——耐科斯特,聚乙二醇化胰岛素——耐科斯特。
Drugs R D. 2004;5(3):166-70. doi: 10.2165/00126839-200405030-00007.
6
Air and soul: the science and application of aerosol therapy.空气与灵魂:气溶胶治疗的科学与应用。
Respir Care. 2010 Jul;55(7):911-21.
7
Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.人体全肺气道模型中颗粒传输与沉积的高效计算分析。第二部分:干粉吸入器应用。
Comput Biol Med. 2017 May 1;84:247-253. doi: 10.1016/j.compbiomed.2016.10.025. Epub 2016 Nov 3.
8
Delivery Technologies for Orally Inhaled Products: an Update.口服吸入制剂的给药技术:更新。
AAPS PharmSciTech. 2019 Feb 19;20(3):117. doi: 10.1208/s12249-019-1314-2.
9
Drug Delivery Devices for Inhaled Medicines.吸入药物的给药装置
Handb Exp Pharmacol. 2017;237:265-280. doi: 10.1007/164_2016_67.
10
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.吸入装置在哮喘和慢性阻塞性气道疾病中的有效性比较:文献系统评价
Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.

引用本文的文献

1
Impact of Improper Inhaler Technique on Pediatric Asthma Control in Vietnam: A Cross-Sectional Study.吸入器技术不当对越南儿童哮喘控制的影响:一项横断面研究。
Sage Open Pediatr. 2025 Apr 15;12:30502225251325625. doi: 10.1177/30502225251325625. eCollection 2025 Jan-Dec.

本文引用的文献

1
Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens.针对呼吸道病原体的新一代黏膜疫苗策略
Vaccines (Basel). 2023 Oct 12;11(10):1585. doi: 10.3390/vaccines11101585.
2
Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.新型靶向慢性阻塞性肺疾病氧化应激的药物传递系统:综述。
J Nanobiotechnology. 2020 Oct 19;18(1):145. doi: 10.1186/s12951-020-00703-5.
3
Advances in Pulmonary Drug Delivery.肺部给药的进展
Pharmaceutics. 2020 Sep 23;12(10):911. doi: 10.3390/pharmaceutics12100911.
4
Nanotechnology-based antiviral therapeutics.基于纳米技术的抗病毒疗法。
Drug Deliv Transl Res. 2021 Jun;11(3):748-787. doi: 10.1007/s13346-020-00818-0.
5
Future Trends in Nebulized Therapies for Pulmonary Disease.肺部疾病雾化治疗的未来趋势
J Pers Med. 2020 May 10;10(2):37. doi: 10.3390/jpm10020037.
6
Challenges and strategies in drug delivery systems for treatment of pulmonary infections.肺部感染治疗中药物传递系统的挑战与策略。
Eur J Pharm Biopharm. 2019 Nov;144:110-124. doi: 10.1016/j.ejpb.2019.09.002. Epub 2019 Sep 4.
7
Drug delivery to the lungs: challenges and opportunities.肺部给药:挑战与机遇
Ther Deliv. 2017 Jul;8(8):647-661. doi: 10.4155/tde-2017-0037.
8
Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.纳米颗粒化疗药物的肺部给药用于肺癌治疗:挑战与机遇
Acta Pharmacol Sin. 2017 Jun;38(6):782-797. doi: 10.1038/aps.2017.34. Epub 2017 May 1.
9
Recent advances in testing of microsphere drug delivery systems.微球药物递送系统检测的最新进展。
Expert Opin Drug Deliv. 2016;13(4):593-608. doi: 10.1517/17425247.2016.1134484. Epub 2016 Feb 1.
10
Inhaled formulations and pulmonary drug delivery systems for respiratory infections.用于呼吸道感染的吸入制剂和肺部药物输送系统。
Adv Drug Deliv Rev. 2015 May;85:83-99. doi: 10.1016/j.addr.2014.10.022. Epub 2014 Oct 24.